冠状动脉支架术后无阿司匹林与双联抗血小板策略:STOPDAPT-3随机试验
STOPDAPT-3随机试验纳入6002例急性冠脉综合征或高出血风险患者,比较PCI术前给予普拉格雷单药(无阿司匹林)与阿司匹林联合普拉格雷双联抗血小板治疗。1个月时,无阿司匹林组在大出血主要终点未显示优效性(4.47% vs 4.71%,HR 0.95,95%CI 0.75-1.20,P=0.66),心血管事件主要终点非劣效(4.12% vs 3.69%,HR 1.12,95%CI 0.87-1.45,非劣效P=0.01),但无阿司匹林组计划外冠状动脉血运重建和亚急性明确或可能支架血栓形成有增加信号。
要点
- 无阿司匹林组1个月大出血未优于DAPT组(4.47% vs 4.71%,HR 0.95,95%CI 0.75-1.20)。
- 无阿司匹林组心血管事件非劣效于DAPT组(4.12% vs 3.69%,HR 1.12,95%CI 0.87-1.45)。
- 无阿司匹林组计划外血运重建和亚急性支架血栓形成有增加信号。
核心结论
- 低剂量普拉格雷单药无阿司匹林策略相比DAPT未能证明在PCI后1个月内对大出血的优效性,但心血管事件非劣效。
- 无阿司匹林策略与冠状动脉事件增加信号相关。
研究设计与样本
- 随机对照试验,纳入6002例急性冠脉综合征或高出血风险患者,在PCI术前随机分组。
- 全分析集5966例:无阿司匹林组2984例,DAPT组2982例;年龄71.6±11.7岁,男性76.6%,急性冠脉综合征75.0%。
主要发现
- 1个月时主要出血终点:无阿司匹林组4.47%,DAPT组4.71%;HR 0.95(95%CI 0.75-1.20),优效性P=0.66。
- 1个月时主要心血管事件终点:无阿司匹林组4.12%,DAPT组3.69%;HR 1.12(95%CI 0.87-1.45),非劣效性P=0.01。
- 无阿司匹林组计划外冠状动脉血运重建1.05% vs 0.57%,HR 1.83(95%CI 1.01-3.30)。
- 无阿司匹林组亚急性明确或可能支架血栓形成0.58% vs 0.17%,HR 3.40(95%CI 1.26-9.23)。
关键数值与推荐
- 两组均给予20 mg普拉格雷负荷,无阿司匹林组普拉格雷3.75 mg/日单药,DAPT组阿司匹林81-100 mg/日联合普拉格雷3.75 mg/日。
- 主要出血终点为BARC 3或5型出血,主要心血管事件终点为心血管死亡、心肌梗死、明确支架血栓形成或缺血性卒中的复合终点。
- 1个月时两组方案依从性均为88%。
临床怎么用
- 对于急性冠脉综合征或高出血风险PCI患者,无阿司匹林普拉格雷单药策略未减少1个月内大出血,且冠状动脉事件有增加信号,不支持常规替代DAPT。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Bleeding rates on dual antiplatelet therapy (DAPT) within 1 month after percutaneous coronary intervention (PCI) remain high in clinical practice, particularly in patients with acute coronary syndrome or high bleeding risk. Aspirin-free strategy might result in lower bleeding early after PCI without increasing cardiovascular events, but its efficacy and safety have not yet been proven in randomized trials. METHODS: We randomly assigned 6002 patients with acute coronary syndrome or high bleeding risk just before PCI either to prasugrel (3.75 mg/day) monotherapy or to DAPT with aspirin (81-100 mg/day) and prasugrel (3.75 mg/day) after loading of 20 mg of prasugrel in both groups. The coprimary end points were major bleeding (Bleeding Academic Research Consortium 3 or 5) for superiority and cardiovascular events (a composite of cardiovascular death, myocardial infarction, definite stent thrombosis, or ischemic stroke) for noninferiority with a relative 50% margin. RESULTS: The full analysis set population consisted of 5966 patients (no-aspirin group, 2984 patients; DAPT group, 2982 patients; age, 71.6±11.7 years; men, 76.6%; acute coronary syndrome, 75.0%). Within 7 days before randomization, aspirin alone, aspirin with P2Y12 inhibitor, oral anticoagulants, and intravenous heparin infusion were given in 21.3%, 6.4%, 8.9%, and 24.5%, respectively. Adherence to the protocol-specified antiplatelet therapy was 88% in both groups at 1 month. At 1 month, the no-aspirin group was not superior to the DAPT group for the coprimary bleeding end point (4.47% and 4.71%; hazard ratio, 0.95 [95% CI, 0.75-1.20]; Psuperiority=0.66). The no-aspirin group was noninferior to the DAPT group for the coprimary cardiovascular end point (4.12% and 3.69%; hazard ratio, 1.12 [95% CI, 0.87-1.45]; Pnoninferiority=0.01). There was no difference in net adverse clinical outcomes and each component of coprimary cardiovascular end point. There was an excess of any unplanned coronary revascularization (1.05% and 0.57%; hazard ratio, 1.83 [95%CI, 1.01-3.30]) and subacute definite or probable stent thrombosis (0.58% and 0.17%; hazard ratio, 3.40 [95% CI, 1.26-9.23]) in the no-aspirin group compared with the DAPT group. CONCLUSIONS: The aspirin-free strategy using low-dose prasugrel compared with the DAPT strategy failed to attest superiority for major bleeding within 1 month after PCI but was noninferior for cardiovascular events within 1 month after PCI. However, the aspirin-free strategy was associated with a signal suggesting an excess of coronary events. REGISTRATION: URL: https://www.clinicaltrials.gov; Unique identifier: NCT04609111.
引用
- Natsuaki, Watanabe, Morimoto, et al. An Aspirin-Free Versus Dual Antiplatelet Strategy for Coronary Stenting: STOPDAPT-3 Randomized Trial. Circulation. 2023. PMID: 37994553. doi:10.1161/CIRCULATIONAHA.123.066720
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。